XRCC1 and lung carcinoma: There was no statistically significant evidence for an influence of the XRCC1 Arg399Gln polymorphism on median PFS of advanced lung cancer patients treated with platinum-based chemotherapy (GlnGln vs. ArgArg: HR = 0.80, 95% CI, 0.58–1.11, P = 0.179, Fig. 3C; GlnArg vs. ArgArg: HR = 0.91, 95% CI, 0.71–1.17, P = 0.468; GlnGln+GlnArg vs. ArgArg: HR, = 0.86, 95% CI, 0.70–1.06, P = 1.38, Table 4).